The future of affordable cancer immunotherapy.
RNA-based vaccines
adoptive cell therapy
affordable
biomarkers
immunohistochemistry
immunotherapy
microbiome
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
06
2023
accepted:
11
08
2023
medline:
25
9
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
epublish
Résumé
The treatment of cancer was revolutionized within the last two decades by utilizing the mechanism of the immune system against malignant tissue in so-called cancer immunotherapy. Two main developments boosted cancer immunotherapy: 1) the use of checkpoint inhibitors, which are characterized by a relatively high response rate mainly in solid tumors; however, at the cost of serious side effects, and 2) the use of chimeric antigen receptor (CAR)-T cells, which were shown to be very efficient in the treatment of hematologic malignancies, but failed to show high clinical effectiveness in solid tumors until now. In addition, active immunization against individual tumors is emerging, and the first products have reached clinical approval. These new treatment options are very cost-intensive and are not financially compensated by health insurance in many countries. Hence, strategies must be developed to make cancer immunotherapy affordable and to improve the cost-benefit ratio. In this review, we discuss the following strategies: 1) to leverage the antigenicity of "cold tumors" with affordable reagents, 2) to use microbiome-based products as markers or therapeutics, 3) to apply measures that make adoptive cell therapy (ACT) cheaper, e.g., the use of off-the-shelf products, 4) to use immunotherapies that offer cheaper platforms, such as RNA- or peptide-based vaccines and vaccines that use shared or common antigens instead of highly personal antigens, 5) to use a small set of predictive biomarkers instead of the "sequence everything" approach, and 6) to explore affordable immunohistochemistry markers that may direct individual therapies.
Identifiants
pubmed: 37736099
doi: 10.3389/fimmu.2023.1248867
pmc: PMC10509759
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1248867Informations de copyright
Copyright © 2023 Schaft, Dörrie, Schuler, Schuler-Thurner, Sallam, Klein, Eisenberg, Frankenburg, Lotem and Khatib.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Cell Proteomics. 2021;20:100022
pubmed: 33583769
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Nature. 2001 Oct 18;413(6857):732-8
pubmed: 11607032
Cell. 2021 Jul 22;184(15):4032-4047.e31
pubmed: 34171309
J Clin Invest. 2020 Nov 2;130(11):5976-5988
pubmed: 33016924
Nature. 2020 Sep;585(7823):107-112
pubmed: 32728218
J Immunol Res. 2022 Mar 18;2022:8052212
pubmed: 35340585
Pharmaceutics. 2020 Jan 23;12(2):
pubmed: 31979205
Immune Netw. 2020 Mar 09;20(2):e14
pubmed: 32395366
Biomedicines. 2020 Dec 17;8(12):
pubmed: 33348704
Oncoimmunology. 2022 Jul 4;11(1):2096363
pubmed: 35800158
Hum Vaccin Immunother. 2013 Oct;9(10):2263-76
pubmed: 23921513
Science. 2021 Feb 5;371(6529):602-609
pubmed: 33303685
Stem Cells Transl Med. 2021 Jul;10(7):987-995
pubmed: 33634954
Genome Med. 2019 Oct 9;11(1):61
pubmed: 31597568
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Cancer Immunol Res. 2013 Jul;1(1):26-31
pubmed: 24777247
JAMA Netw Open. 2020 Apr 1;3(4):e202895
pubmed: 32297948
Neuromuscul Disord. 2019 Nov;29(11):842-856
pubmed: 31704158
Pathogens. 2023 Jul 15;12(7):
pubmed: 37513787
Stem Cells Transl Med. 2019 May;8(5):441-449
pubmed: 30735000
Science. 2023 Jun 9;380(6649):eabo2296
pubmed: 37289890
Mod Pathol. 2014 Oct;27(10):1321-30
pubmed: 24633195
Cell Stem Cell. 2023 May 4;30(5):592-610
pubmed: 36948187
Int J Cancer. 2005 Aug 10;116(1):87-93
pubmed: 15756674
Nat Biomed Eng. 2019 Dec;3(12):974-984
pubmed: 31182835
Nat Cancer. 2022 May;3(5):536-546
pubmed: 35624337
Gastroenterology. 2018 Jul;155(1):29-32
pubmed: 29567081
Arch Pathol Lab Med. 2016 Apr;140(4):355-7
pubmed: 26340412
Clin Cancer Res. 2002 Dec;8(12):3702-9
pubmed: 12473579
Mol Ther. 2023 Mar 1;31(3):631-646
pubmed: 36463401
Front Immunol. 2023 Apr 19;14:1176724
pubmed: 37153585
Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):E1591-9
pubmed: 24715725
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
J Clin Oncol. 2022 Jun 1;40(16):1741-1754
pubmed: 35104158
Trends Immunol. 2022 Jul;43(7):523-545
pubmed: 35624021
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Pathol Res Pract. 2023 Jul;247:154583
pubmed: 37267723
Ther Adv Vaccines. 2014 Jan;2(1):10-31
pubmed: 24757523
Semin Oncol. 2022 Feb;49(1):60-68
pubmed: 35123801
Curr Opin Immunol. 2020 Jun;64:130-136
pubmed: 32615334
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
PLoS One. 2012;7(3):e33571
pubmed: 22442699
Genome Biol. 2021 Jan 4;22(1):9
pubmed: 33397462
Bone Marrow Transplant. 2019 Aug;54(8):1208-1217
pubmed: 30518980
Front Immunol. 2022 Dec 14;13:1029069
pubmed: 36591226
J Immunol. 2009 Jan 1;182(1):164-70
pubmed: 19109147
Blood. 1999 Jul 1;94(1):333-9
pubmed: 10381530
Int J Cancer. 2020 Dec 15;147(12):3438-3445
pubmed: 32535920
Nat Med. 2018 Jun;24(6):724-730
pubmed: 29867227
Front Oncol. 2022 Feb 16;12:847350
pubmed: 35252014
Nat Biotechnol. 2014 Mar;32(3):252-60
pubmed: 24561556
Front Immunol. 2022 Feb 04;13:785231
pubmed: 35185883
CNS Drugs. 2019 Sep;33(9):919-932
pubmed: 31420846
World J Gastroenterol. 2021 Nov 14;27(42):7340-7349
pubmed: 34876793
J Immunol. 2001 Oct 1;167(7):4046-50
pubmed: 11564825
Genes (Basel). 2022 Dec 24;14(1):
pubmed: 36672796
Nat Biotechnol. 2019 Mar;37(3):252-258
pubmed: 30778232
Clin Transl Immunology. 2022 Feb 02;11(2):e1373
pubmed: 35136603
Genes Dev. 2006 Dec 15;20(24):3426-39
pubmed: 17182868
Nat Med. 2022 Apr;28(4):713-723
pubmed: 35288695
Gene Ther. 2009 May;16(5):596-604
pubmed: 19158846
Immunity. 1995 Oct;3(4):495-507
pubmed: 7584140
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2021 Feb 5;371(6529):595-602
pubmed: 33542131
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Front Immunol. 2019 Feb 08;10:168
pubmed: 30800125
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
BMC Med. 2016 Oct 25;14(1):168
pubmed: 27776519
Cell. 2019 Jan 10;176(1-2):404
pubmed: 30633907
Cancer Sci. 2012 Aug;103(8):1414-9
pubmed: 22621620
Pathol Res Pract. 2023 Jan;241:154241
pubmed: 36543080
Cells. 2023 Jul 05;12(13):
pubmed: 37443821
Cell Rep Med. 2022 Feb 15;3(2):100500
pubmed: 35243413
Nature. 2016 Aug 4;536(7614):91-5
pubmed: 27350335
Cancers (Basel). 2019 Nov 15;11(11):
pubmed: 31731749
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
BMC Cancer. 2022 Dec 30;22(1):1366
pubmed: 36585700
Cancer Res. 2006 Mar 15;66(6):3331-7
pubmed: 16540688
J Transl Med. 2012 Jan 03;10:1
pubmed: 22214470
Blood. 2018 Sep 6;132(10):1022-1026
pubmed: 29925499
Mol Cell. 2019 Mar 21;73(6):1162-1173.e5
pubmed: 30712990
Cancer Res. 2011 Sep 1;71(17):5601-5
pubmed: 21846822
Clin Cancer Res. 2017 May 1;23(9):2255-2266
pubmed: 27815355
N Engl J Med. 2022 Jun 2;386(22):2112-2119
pubmed: 35648703
Cells. 2021 Dec 01;10(12):
pubmed: 34943898
J Hematol Oncol. 2021 Sep 27;14(1):156
pubmed: 34579759
J Clin Oncol. 2006 May 1;24(13):e20-2
pubmed: 16648493
Cancer Immunol Res. 2017 Dec;5(12):1152-1161
pubmed: 29109077
Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7
pubmed: 30853558
Oncol Lett. 2021 Sep;22(3):655
pubmed: 34386077
BMC Cancer. 2017 Aug 17;17(1):551
pubmed: 28818060
Nature. 2023 Jun;618(7963):144-150
pubmed: 37165196
Nature. 1995 May 11;375(6527):155-8
pubmed: 7753173
Cell Res. 2020 Jun;30(6):507-519
pubmed: 32467593
Ann N Y Acad Sci. 2012 Aug;1266:161-70
pubmed: 22901267
Cancer Immunol Res. 2014 Feb;2(2):112-20
pubmed: 24579088
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12826-12835
pubmed: 32461371
Front Immunol. 2017 Sep 22;8:1178
pubmed: 29018445
Immunity. 2015 Feb 17;42(2):344-355
pubmed: 25680274
Front Oncol. 2023 Apr 11;13:1144534
pubmed: 37114123
Sci Rep. 2019 Oct 2;9(1):14184
pubmed: 31578439